ReviewCurrent pharmaceutical biotechnology2026
Detailed Comprehensive Review on Advancement of Cubosomes and their Currently Available Applications.
Review in Current pharmaceutical biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cubosomes, nanostructured lipid-based carriers, exhibit a promising potential in drug delivery due to their unique structure, which integrates amphiphilic lipids and polymer-based stabilizers. This review examines the scientific principles of digestion relevant to cubosome function, their structural and compositional aspects, and various processing methods. We also explore potential distribution pathways, drug delivery strategies, and therapeutic applications, including cancer therapy, antimicrobial therapy, vaccine delivery, ocular and dermatological applications, and transdermal delivery. Notably, some challenges still hinder the clinical application of cubosome products, which this review addresses. This paper aims to provide an in-depth discussion on cubosomes, encompassing their composition, theories, processing techniques, and the diverse administration routes that make them a versatile option for targeted drug delivery. A bibliographic review was conducted using major electronic databases (PubMed, ScienceDirect, Scopus, Google Scholar, Springer, and Wiley) along with offline and online academic libraries for comprehensive data collection. Cubosomes, as innovative lipid-based nanotechnology similar to liposomes and niosomes, possess significant potential due to their unique bioadhesive properties, thermodynamic stability, and capability to encapsulate a variety of compounds. Composed typically of glyceryl monooleate and Phytantriol with a stabilizer, cubosomes enable sustained and targeted release, suggesting a broad range of applications. Further advancements are needed to address current limitations in their practical application.
Indexed as
Identifiers
40197193What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.